Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Center for Personalized Cancer Therapy and Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, Moores Cancer Center, La Jolla, California, USA.
Clin Pharmacol Ther. 2018 Feb;103(2):206-209. doi: 10.1002/cpt.920. Epub 2017 Nov 14.
Technological advances in high-throughput next-generation sequencing (NGS) along with advances in computational processes have brought about the dawn of the genomic medicine era. NGS has enabled molecular characterization of malignancies, and facilitated the development and approval of gene- and immune-targeted therapies, both of which impact the mutanome. Clinical implementation of this technology, approval of novel targeted agents, and establishment of molecular tumor boards has enabled precision oncology to become a reality.
高通量下一代测序（NGS）技术的进步以及计算过程的进步带来了基因组医学时代的曙光。NGS 实现了恶性肿瘤的分子特征分析，并促进了基因和免疫靶向治疗的发展和批准，这两者都影响了突变组。该技术的临床应用、新型靶向药物的批准以及分子肿瘤委员会的建立使精准肿瘤学成为现实。
